Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With Chemoradiation: An Analysis of the Radiation Therapy Oncology Group
Purpose Patients treated with chemoradiotherapy for locally advanced non–small-cell lung carcinoma (LA-NSCLC) were analyzed for local-regional failure (LRF) and overall survival (OS) with respect to radiotherapy dose intensity. Methods and Materials This study combined data from seven Radiation Ther...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2012-01, Vol.82 (1), p.425-434 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 434 |
|---|---|
| container_issue | 1 |
| container_start_page | 425 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 82 |
| creator | Machtay, Mitchell, M.D Bae, Kyounghwa, Ph.D Movsas, Benjamin, M.D Paulus, Rebecca, B.S Gore, Elizabeth M., M.D Komaki, Ritsuko, M.D Albain, Kathy, M.D Sause, William T., M.D Curran, Walter J., M.D |
| description | Purpose Patients treated with chemoradiotherapy for locally advanced non–small-cell lung carcinoma (LA-NSCLC) were analyzed for local-regional failure (LRF) and overall survival (OS) with respect to radiotherapy dose intensity. Methods and Materials This study combined data from seven Radiation Therapy Oncology Group (RTOG) trials in which chemoradiotherapy was used for LA-NSCLC: RTOG 88-08 (chemoradiation arm only), 90-15, 91-06, 92-04, 93-09 (nonoperative arm only), 94-10, and 98-01. The radiotherapeutic biologically effective dose (BED) received by each individual patient was calculated, as was the overall treatment time-adjusted BED (tBED) using standard formulae. Heterogeneity testing was done with chi-squared statistics, and weighted pooled hazard ratio estimates were used. Cox and Fine and Gray’s proportional hazard models were used for OS and LRF, respectively, to test the associations between BED and tBED adjusted for other covariates. Results A total of 1,356 patients were analyzed for BED (1,348 for tBED). The 2-year and 5-year OS rates were 38% and 15%, respectively. The 2-year and 5-year LRF rates were 46% and 52%, respectively. The BED (and tBED) were highly significantly associated with both OS and LRF, with or without adjustment for other covariates on multivariate analysis ( p < 0.0001). A 1-Gy BED increase in radiotherapy dose intensity was statistically significantly associated with approximately 4% relative improvement in survival; this is another way of expressing the finding that the pool-adjusted hazard ratio for survival as a function of BED was 0.96. Similarly, a 1-Gy tBED increase in radiotherapy dose intensity was statistically significantly associated with approximately 3% relative improvement in local-regional control; this is another way of expressing the finding that the pool-adjusted hazard ratio as a function of tBED was 0.97. Conclusions Higher radiotherapy dose intensity is associated with improved local-regional control and survival in the setting of chemoradiotherapy. |
| doi_str_mv | 10.1016/j.ijrobp.2010.09.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5764542</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0360301610032414</els_id><sourcerecordid>912272370</sourcerecordid><originalsourceid>FETCH-LOGICAL-c578t-321dbd3f2d73bc91c4571b353907a33e6afd7615ef7750f8e6aaedf6fc9db183</originalsourceid><addsrcrecordid>eNqFUk2P0zAQjRCIXRb-AUKWOMClxR9JnHBYqZRlt1JFJbYS3CzHcVqXxBPspFJu_Ad-Hxd-Cc627AIHkCJHnnnzZt74RdFTgqcEk_TVbmp2Dop2SnEI4XyKcXwvOiUZzycsST7dj04xS_GEBfBJ9Mj7HcaYEB4_jE4ozrNQlZ1G36_MZqsdemOgho1Rsq4HdFFVWnVmr9Fb8BpBhT7I0kAXgLId0MKjmfegjOx0iT6abosWTetgH26rvlPQaI8qcGgJB75ZuZdWhex7sD--frtuQhTNdTiWvd2guXTKWGgkWjt9xznf6gZcaCw7A_Y1mtnwyXrwxo8jhWluxrrJovVxtpVVo5ABXTro28fRg0rWXj85_s-i9buL9fxqslxdLuaz5UQlPOsmjJKyKFlFS84KlRMVJ5wULGE55pIxncqq5ClJdMV5gqssBKQuq7RSeVmQjJ1F5wfati8aXSptOydr0TrTSDcIkEb8mbFmKzawFwlP4ySmgeD5gQB8Z4RXptNqq8Da8AyCUpwkOY8D6sWxjYMvvfadaIxXYY3Saui9yAmlnDKOA_LlP5EE4yxjNGd5gMYHqHLgvdPV7dgEi9FoYicORhOj0QTORTBaKHv2u-Tbol_OutuJDnvfG-1GWXp0gXGjqhLM_zr8TaBqY0eHftaD9jvoXXBD0CI8FVhcj2YfvR60MRqTmP0Eu9oBKg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1008832939</pqid></control><display><type>article</type><title>Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With Chemoradiation: An Analysis of the Radiation Therapy Oncology Group</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Machtay, Mitchell, M.D ; Bae, Kyounghwa, Ph.D ; Movsas, Benjamin, M.D ; Paulus, Rebecca, B.S ; Gore, Elizabeth M., M.D ; Komaki, Ritsuko, M.D ; Albain, Kathy, M.D ; Sause, William T., M.D ; Curran, Walter J., M.D</creator><creatorcontrib>Machtay, Mitchell, M.D ; Bae, Kyounghwa, Ph.D ; Movsas, Benjamin, M.D ; Paulus, Rebecca, B.S ; Gore, Elizabeth M., M.D ; Komaki, Ritsuko, M.D ; Albain, Kathy, M.D ; Sause, William T., M.D ; Curran, Walter J., M.D</creatorcontrib><description>Purpose Patients treated with chemoradiotherapy for locally advanced non–small-cell lung carcinoma (LA-NSCLC) were analyzed for local-regional failure (LRF) and overall survival (OS) with respect to radiotherapy dose intensity. Methods and Materials This study combined data from seven Radiation Therapy Oncology Group (RTOG) trials in which chemoradiotherapy was used for LA-NSCLC: RTOG 88-08 (chemoradiation arm only), 90-15, 91-06, 92-04, 93-09 (nonoperative arm only), 94-10, and 98-01. The radiotherapeutic biologically effective dose (BED) received by each individual patient was calculated, as was the overall treatment time-adjusted BED (tBED) using standard formulae. Heterogeneity testing was done with chi-squared statistics, and weighted pooled hazard ratio estimates were used. Cox and Fine and Gray’s proportional hazard models were used for OS and LRF, respectively, to test the associations between BED and tBED adjusted for other covariates. Results A total of 1,356 patients were analyzed for BED (1,348 for tBED). The 2-year and 5-year OS rates were 38% and 15%, respectively. The 2-year and 5-year LRF rates were 46% and 52%, respectively. The BED (and tBED) were highly significantly associated with both OS and LRF, with or without adjustment for other covariates on multivariate analysis ( p < 0.0001). A 1-Gy BED increase in radiotherapy dose intensity was statistically significantly associated with approximately 4% relative improvement in survival; this is another way of expressing the finding that the pool-adjusted hazard ratio for survival as a function of BED was 0.96. Similarly, a 1-Gy tBED increase in radiotherapy dose intensity was statistically significantly associated with approximately 3% relative improvement in local-regional control; this is another way of expressing the finding that the pool-adjusted hazard ratio as a function of tBED was 0.97. Conclusions Higher radiotherapy dose intensity is associated with improved local-regional control and survival in the setting of chemoradiotherapy.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2010.09.004</identifier><identifier>PMID: 20980108</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject><![CDATA[Adult ; Advanced non–small-cell lung carcinoma ; Aged ; Aged, 80 and over ; Amifostine - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carboplatin - administration & dosage ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - secondary ; Carcinoma, Non-Small-Cell Lung - therapy ; CARCINOMAS ; Chemoradiotherapy ; Chemoradiotherapy - methods ; Cisplatin - administration & dosage ; Clinical trials ; COMBINED THERAPY ; Data processing ; Dose-response effects ; Etoposide - administration & dosage ; FAILURES ; Female ; HAZARDS ; Hematology, Oncology and Palliative Medicine ; Humans ; Local-regional failure ; Lung ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; LUNGS ; Male ; Middle Aged ; MULTIVARIATE ANALYSIS ; Non-small cell lung carcinoma ; Oncology ; Paclitaxel - administration & dosage ; PATIENTS ; Proportional Hazards Models ; Radiation ; RADIATION DOSES ; Radiation oncology ; Radiation therapy ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Radiotherapy Dosage ; Relative Biological Effectiveness ; Retrospective Studies ; Statistical analysis ; Survival ; Survival Analysis ; Survival with respect to radiotherapy dose intensity ; TESTING ; Treatment Failure ; Vinblastine - administration & dosage]]></subject><ispartof>International journal of radiation oncology, biology, physics, 2012-01, Vol.82 (1), p.425-434</ispartof><rights>Elsevier Inc.</rights><rights>2012 Elsevier Inc.</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c578t-321dbd3f2d73bc91c4571b353907a33e6afd7615ef7750f8e6aaedf6fc9db183</citedby><cites>FETCH-LOGICAL-c578t-321dbd3f2d73bc91c4571b353907a33e6afd7615ef7750f8e6aaedf6fc9db183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2010.09.004$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,777,781,882,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20980108$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22055974$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Machtay, Mitchell, M.D</creatorcontrib><creatorcontrib>Bae, Kyounghwa, Ph.D</creatorcontrib><creatorcontrib>Movsas, Benjamin, M.D</creatorcontrib><creatorcontrib>Paulus, Rebecca, B.S</creatorcontrib><creatorcontrib>Gore, Elizabeth M., M.D</creatorcontrib><creatorcontrib>Komaki, Ritsuko, M.D</creatorcontrib><creatorcontrib>Albain, Kathy, M.D</creatorcontrib><creatorcontrib>Sause, William T., M.D</creatorcontrib><creatorcontrib>Curran, Walter J., M.D</creatorcontrib><title>Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With Chemoradiation: An Analysis of the Radiation Therapy Oncology Group</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose Patients treated with chemoradiotherapy for locally advanced non–small-cell lung carcinoma (LA-NSCLC) were analyzed for local-regional failure (LRF) and overall survival (OS) with respect to radiotherapy dose intensity. Methods and Materials This study combined data from seven Radiation Therapy Oncology Group (RTOG) trials in which chemoradiotherapy was used for LA-NSCLC: RTOG 88-08 (chemoradiation arm only), 90-15, 91-06, 92-04, 93-09 (nonoperative arm only), 94-10, and 98-01. The radiotherapeutic biologically effective dose (BED) received by each individual patient was calculated, as was the overall treatment time-adjusted BED (tBED) using standard formulae. Heterogeneity testing was done with chi-squared statistics, and weighted pooled hazard ratio estimates were used. Cox and Fine and Gray’s proportional hazard models were used for OS and LRF, respectively, to test the associations between BED and tBED adjusted for other covariates. Results A total of 1,356 patients were analyzed for BED (1,348 for tBED). The 2-year and 5-year OS rates were 38% and 15%, respectively. The 2-year and 5-year LRF rates were 46% and 52%, respectively. The BED (and tBED) were highly significantly associated with both OS and LRF, with or without adjustment for other covariates on multivariate analysis ( p < 0.0001). A 1-Gy BED increase in radiotherapy dose intensity was statistically significantly associated with approximately 4% relative improvement in survival; this is another way of expressing the finding that the pool-adjusted hazard ratio for survival as a function of BED was 0.96. Similarly, a 1-Gy tBED increase in radiotherapy dose intensity was statistically significantly associated with approximately 3% relative improvement in local-regional control; this is another way of expressing the finding that the pool-adjusted hazard ratio as a function of tBED was 0.97. Conclusions Higher radiotherapy dose intensity is associated with improved local-regional control and survival in the setting of chemoradiotherapy.</description><subject>Adult</subject><subject>Advanced non–small-cell lung carcinoma</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amifostine - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - secondary</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>CARCINOMAS</subject><subject>Chemoradiotherapy</subject><subject>Chemoradiotherapy - methods</subject><subject>Cisplatin - administration & dosage</subject><subject>Clinical trials</subject><subject>COMBINED THERAPY</subject><subject>Data processing</subject><subject>Dose-response effects</subject><subject>Etoposide - administration & dosage</subject><subject>FAILURES</subject><subject>Female</subject><subject>HAZARDS</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Local-regional failure</subject><subject>Lung</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>LUNGS</subject><subject>Male</subject><subject>Middle Aged</subject><subject>MULTIVARIATE ANALYSIS</subject><subject>Non-small cell lung carcinoma</subject><subject>Oncology</subject><subject>Paclitaxel - administration & dosage</subject><subject>PATIENTS</subject><subject>Proportional Hazards Models</subject><subject>Radiation</subject><subject>RADIATION DOSES</subject><subject>Radiation oncology</subject><subject>Radiation therapy</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>Radiotherapy Dosage</subject><subject>Relative Biological Effectiveness</subject><subject>Retrospective Studies</subject><subject>Statistical analysis</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Survival with respect to radiotherapy dose intensity</subject><subject>TESTING</subject><subject>Treatment Failure</subject><subject>Vinblastine - administration & dosage</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUk2P0zAQjRCIXRb-AUKWOMClxR9JnHBYqZRlt1JFJbYS3CzHcVqXxBPspFJu_Ad-Hxd-Cc627AIHkCJHnnnzZt74RdFTgqcEk_TVbmp2Dop2SnEI4XyKcXwvOiUZzycsST7dj04xS_GEBfBJ9Mj7HcaYEB4_jE4ozrNQlZ1G36_MZqsdemOgho1Rsq4HdFFVWnVmr9Fb8BpBhT7I0kAXgLId0MKjmfegjOx0iT6abosWTetgH26rvlPQaI8qcGgJB75ZuZdWhex7sD--frtuQhTNdTiWvd2guXTKWGgkWjt9xznf6gZcaCw7A_Y1mtnwyXrwxo8jhWluxrrJovVxtpVVo5ABXTro28fRg0rWXj85_s-i9buL9fxqslxdLuaz5UQlPOsmjJKyKFlFS84KlRMVJ5wULGE55pIxncqq5ClJdMV5gqssBKQuq7RSeVmQjJ1F5wfati8aXSptOydr0TrTSDcIkEb8mbFmKzawFwlP4ySmgeD5gQB8Z4RXptNqq8Da8AyCUpwkOY8D6sWxjYMvvfadaIxXYY3Saui9yAmlnDKOA_LlP5EE4yxjNGd5gMYHqHLgvdPV7dgEi9FoYicORhOj0QTORTBaKHv2u-Tbol_OutuJDnvfG-1GWXp0gXGjqhLM_zr8TaBqY0eHftaD9jvoXXBD0CI8FVhcj2YfvR60MRqTmP0Eu9oBKg</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Machtay, Mitchell, M.D</creator><creator>Bae, Kyounghwa, Ph.D</creator><creator>Movsas, Benjamin, M.D</creator><creator>Paulus, Rebecca, B.S</creator><creator>Gore, Elizabeth M., M.D</creator><creator>Komaki, Ritsuko, M.D</creator><creator>Albain, Kathy, M.D</creator><creator>Sause, William T., M.D</creator><creator>Curran, Walter J., M.D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7ST</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>SOI</scope><scope>7X8</scope><scope>OTOTI</scope><scope>5PM</scope></search><sort><creationdate>20120101</creationdate><title>Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With Chemoradiation: An Analysis of the Radiation Therapy Oncology Group</title><author>Machtay, Mitchell, M.D ; Bae, Kyounghwa, Ph.D ; Movsas, Benjamin, M.D ; Paulus, Rebecca, B.S ; Gore, Elizabeth M., M.D ; Komaki, Ritsuko, M.D ; Albain, Kathy, M.D ; Sause, William T., M.D ; Curran, Walter J., M.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c578t-321dbd3f2d73bc91c4571b353907a33e6afd7615ef7750f8e6aaedf6fc9db183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Advanced non–small-cell lung carcinoma</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amifostine - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - secondary</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>CARCINOMAS</topic><topic>Chemoradiotherapy</topic><topic>Chemoradiotherapy - methods</topic><topic>Cisplatin - administration & dosage</topic><topic>Clinical trials</topic><topic>COMBINED THERAPY</topic><topic>Data processing</topic><topic>Dose-response effects</topic><topic>Etoposide - administration & dosage</topic><topic>FAILURES</topic><topic>Female</topic><topic>HAZARDS</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Local-regional failure</topic><topic>Lung</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>LUNGS</topic><topic>Male</topic><topic>Middle Aged</topic><topic>MULTIVARIATE ANALYSIS</topic><topic>Non-small cell lung carcinoma</topic><topic>Oncology</topic><topic>Paclitaxel - administration & dosage</topic><topic>PATIENTS</topic><topic>Proportional Hazards Models</topic><topic>Radiation</topic><topic>RADIATION DOSES</topic><topic>Radiation oncology</topic><topic>Radiation therapy</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>Radiotherapy Dosage</topic><topic>Relative Biological Effectiveness</topic><topic>Retrospective Studies</topic><topic>Statistical analysis</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Survival with respect to radiotherapy dose intensity</topic><topic>TESTING</topic><topic>Treatment Failure</topic><topic>Vinblastine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Machtay, Mitchell, M.D</creatorcontrib><creatorcontrib>Bae, Kyounghwa, Ph.D</creatorcontrib><creatorcontrib>Movsas, Benjamin, M.D</creatorcontrib><creatorcontrib>Paulus, Rebecca, B.S</creatorcontrib><creatorcontrib>Gore, Elizabeth M., M.D</creatorcontrib><creatorcontrib>Komaki, Ritsuko, M.D</creatorcontrib><creatorcontrib>Albain, Kathy, M.D</creatorcontrib><creatorcontrib>Sause, William T., M.D</creatorcontrib><creatorcontrib>Curran, Walter J., M.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Environment Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Machtay, Mitchell, M.D</au><au>Bae, Kyounghwa, Ph.D</au><au>Movsas, Benjamin, M.D</au><au>Paulus, Rebecca, B.S</au><au>Gore, Elizabeth M., M.D</au><au>Komaki, Ritsuko, M.D</au><au>Albain, Kathy, M.D</au><au>Sause, William T., M.D</au><au>Curran, Walter J., M.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With Chemoradiation: An Analysis of the Radiation Therapy Oncology Group</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>82</volume><issue>1</issue><spage>425</spage><epage>434</epage><pages>425-434</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose Patients treated with chemoradiotherapy for locally advanced non–small-cell lung carcinoma (LA-NSCLC) were analyzed for local-regional failure (LRF) and overall survival (OS) with respect to radiotherapy dose intensity. Methods and Materials This study combined data from seven Radiation Therapy Oncology Group (RTOG) trials in which chemoradiotherapy was used for LA-NSCLC: RTOG 88-08 (chemoradiation arm only), 90-15, 91-06, 92-04, 93-09 (nonoperative arm only), 94-10, and 98-01. The radiotherapeutic biologically effective dose (BED) received by each individual patient was calculated, as was the overall treatment time-adjusted BED (tBED) using standard formulae. Heterogeneity testing was done with chi-squared statistics, and weighted pooled hazard ratio estimates were used. Cox and Fine and Gray’s proportional hazard models were used for OS and LRF, respectively, to test the associations between BED and tBED adjusted for other covariates. Results A total of 1,356 patients were analyzed for BED (1,348 for tBED). The 2-year and 5-year OS rates were 38% and 15%, respectively. The 2-year and 5-year LRF rates were 46% and 52%, respectively. The BED (and tBED) were highly significantly associated with both OS and LRF, with or without adjustment for other covariates on multivariate analysis ( p < 0.0001). A 1-Gy BED increase in radiotherapy dose intensity was statistically significantly associated with approximately 4% relative improvement in survival; this is another way of expressing the finding that the pool-adjusted hazard ratio for survival as a function of BED was 0.96. Similarly, a 1-Gy tBED increase in radiotherapy dose intensity was statistically significantly associated with approximately 3% relative improvement in local-regional control; this is another way of expressing the finding that the pool-adjusted hazard ratio as a function of tBED was 0.97. Conclusions Higher radiotherapy dose intensity is associated with improved local-regional control and survival in the setting of chemoradiotherapy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20980108</pmid><doi>10.1016/j.ijrobp.2010.09.004</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2012-01, Vol.82 (1), p.425-434 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5764542 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Advanced non–small-cell lung carcinoma Aged Aged, 80 and over Amifostine - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - secondary Carcinoma, Non-Small-Cell Lung - therapy CARCINOMAS Chemoradiotherapy Chemoradiotherapy - methods Cisplatin - administration & dosage Clinical trials COMBINED THERAPY Data processing Dose-response effects Etoposide - administration & dosage FAILURES Female HAZARDS Hematology, Oncology and Palliative Medicine Humans Local-regional failure Lung Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - therapy LUNGS Male Middle Aged MULTIVARIATE ANALYSIS Non-small cell lung carcinoma Oncology Paclitaxel - administration & dosage PATIENTS Proportional Hazards Models Radiation RADIATION DOSES Radiation oncology Radiation therapy Radiology RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY Radiotherapy Dosage Relative Biological Effectiveness Retrospective Studies Statistical analysis Survival Survival Analysis Survival with respect to radiotherapy dose intensity TESTING Treatment Failure Vinblastine - administration & dosage |
| title | Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With Chemoradiation: An Analysis of the Radiation Therapy Oncology Group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T07%3A03%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Higher%20Biologically%20Effective%20Dose%20of%20Radiotherapy%20Is%20Associated%20With%20Improved%20Outcomes%20for%20Locally%20Advanced%20Non%E2%80%93Small%20Cell%20Lung%20Carcinoma%20Treated%20With%20Chemoradiation:%20An%20Analysis%20of%20the%20Radiation%20Therapy%20Oncology%20Group&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Machtay,%20Mitchell,%20M.D&rft.date=2012-01-01&rft.volume=82&rft.issue=1&rft.spage=425&rft.epage=434&rft.pages=425-434&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2010.09.004&rft_dat=%3Cproquest_pubme%3E912272370%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1008832939&rft_id=info:pmid/20980108&rft_els_id=1_s2_0_S0360301610032414&rfr_iscdi=true |